Investigational biosimilar to Herceptin is designed to treat HER2-positive early breast cancer.
Breast Cancer
Latest News
Advertisement
CME Content
Advertisement
Neratinib (Nerlynx) indicated to prevent breast cancer recurrence.
Neratinib, a kinase inhibitor, is indicated to follow therapy with trastuzumab to prevent breast cancer recurrence.
Biosimilar to trastuzumab (Herceptin) observed to have no clinically significant differences than the reference product.
Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.
Biomarker status could indicate palbociclib resistance in patients with estrogen receptor-positive breast cancer.
Certain biomarkers influence outcomes in breast cancer patients treated with palbociclib.
Top articles of the week from The American Journal of Pharmacy Benefits.
Abemaciclib is a CDK4/6 inhibitor being explored in advanced breast cancer.
Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor for advanced breast cancer.
Top articles of the week from Specialty Pharmacy Times.
Some hair care products may cause increased cancer risk.
A new study looks into a potential link between hair care and breast cancer incidence.
Waiting to get treatment for breast cancer results is worse survival outcomes.
Conflicting breast cancer screening recommendations could result in late stage disease.
Top news of the day from across the health care landscape.
Could household pets be the key to treating breast carcinoma?
Breast Cancer Survivors Foundation settled to pay $350,000 to legitimate breast cancer charities.
Overutilization of care can produce disparities between high- and low-income counties.
New findings show that becoming pregnant after breast cancer does not increase the risk of disease recurrence.
Pertuzumab-based regimen found to reduce the risk of invasive breast cancer recurrence by 19%.
Tests provide little to no benefit and can increase a breast cancer patient’s financial burden.
Top news of the day from across the health care landscape.
Collaboration between Novartis and IBM Watson Health integrates real-world data and analytical techniques on breast cancer outcomes.
Noavrtis teams with IBM Watson supercomputer to advance insights into breast cancer treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Q&A: How Pharmacists Can Address Structural Barriers in Obesity Care
5